{"id":20605,"date":"2017-10-13T16:28:53","date_gmt":"2017-10-13T13:28:53","guid":{"rendered":"http:\/\/www.asperbio.com\/?page_id=20605"},"modified":"2020-04-02T13:19:46","modified_gmt":"2020-04-02T10:19:46","slug":"katehhoolaminergiline-polumorfne-ventrikulaarne-tahhukardia","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-cardiogenetics-testid\/katehhoolaminergiline-polumorfne-ventrikulaarne-tahhukardia\/","title":{"rendered":"Katehhoolaminergiline pol\u00fcmorfne ventrikulaarne tahh\u00fckardia"},"content":{"rendered":"<h2>Katehhoolaminergilise pol\u00fcmorfse ventrikulaarse tahh\u00fckardiaga seotud geenide sekveneerimine<\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/Cardio-01.png') repeat-y; padding-left: 40px;\">\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Geenid:<\/strong><\/td>\n<td><em>ANK2, CALM1, CASQ2, KCNJ2, RYR2, TRDN<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #a34c95; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Metoodika:<\/strong><\/td>\n<td>Kodeeriva piirkonna sekveneerimine (NGS).<br \/>\nKoopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #a34c95; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Testi valmimisaeg:<\/strong><\/td>\n<td>6-9 n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #a34c95; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>N\u00f5uded proovi-materjalile:<\/strong><\/td>\n<td>2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n<p>1 \u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l<br \/>\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis pikkusmarkeri juuresolekul olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #a34c95; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Tellimine:<\/strong><\/td>\n<td>Proovimaterjal saata koos <span style=\"color: #a34c95;\"><strong><a style=\"color: #a34c95;\" href=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Cardiogenetics-saatekiri.doc\">saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #a34c95; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<\/div>\n<p><strong>N\u00e4idustused geenitesti tegemiseks<\/strong>:<\/p>\n<p>1. Kliinilise diagnoosi kinnitamine<br \/>\n2. Diferentsiaaldiagnostika<br \/>\n3. Kandluse m\u00e4\u00e4ramine pereliikmetel<br \/>\n4. Ennetav testimine<br \/>\n5. S\u00fcdame seiskumise l\u00e4bi teinud patsientide testimine<br \/>\n6. Prenataalne ja implatatsioonieelne testimine<br \/>\n7. Geneetiline n\u00f5ustamine<\/p>\n<p style=\"text-align: justify;\"><strong>Katehhoolaminergiline pol\u00fcmorfne ventrikulaarne tahh\u00fckardia<\/strong> (KPVT) on p\u00e4rilik r\u00fctmih\u00e4ire, mis v\u00f5ib p\u00f5hjustada minestamist kehalise tegevuse v\u00f5i tugevamate emotsioonide ajel. V\u00f5ib esineda ka s\u00fcdamepekslemist ja pearinglust. S\u00fcmptomite p\u00f5hjuseks on vatsakestest p\u00e4rinev r\u00fctmih\u00e4ire. S\u00fcmptomid avalduvad tavaliselt 7-20 a vanuselt.<\/p>\n<p style=\"text-align: justify;\">Juhul kui sellised ar\u00fctmiad iseeneslikult l\u00f5pevad, v\u00f5ib toimuda spontaanne paranemine.\u00a0<strong>Ventrikulaarne tahh\u00fckardia<\/strong> v\u00f5ib aga areneda vatsakeste virvenduseks ehk <strong>ventrikulaarseks fibrillatsiooniks<\/strong> ja p\u00f5hjustada \u00e4kksurma. F\u00fc\u00fcsilisel pingutusel v\u00f5i tugevamate emotsioonide m\u00f5jul tekkiv \u00e4kksurm v\u00f5ibki olla ainsaks ilminguks varasemalt as\u00fcmptomaatilisel inimesel.<\/p>\n<p style=\"text-align: justify;\">Haiguse esinemissageduseks on hinnatud 1:10000. Haigus p\u00e4randub enamasti autosoom-dominantsel teel. <em>CASQ2<\/em> geeniga seotud KPVT ja <em>TDRN<\/em> geeniga seotud KPVT p\u00e4randub autosoom-retsessiivselt.<\/p>","protected":false},"excerpt":{"rendered":"<p>Katehhoolaminergilise pol\u00fcmorfse ventrikulaarse tahh\u00fckardiaga seotud geenide sekveneerimine Geenid: ANK2, CALM1, CASQ2, KCNJ2, RYR2, TRDN Metoodika: Kodeeriva piirkonna sekveneerimine (NGS). Koopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale. Testi valmimisaeg: 6-9 n\u00e4dalat N\u00f5uded proovi-materjalile: 2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti) 1 \u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":14537,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-20605","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/20605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=20605"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/20605\/revisions"}],"predecessor-version":[{"id":25549,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/20605\/revisions\/25549"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/14537"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=20605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}